Ropes & Gray advised ImmunoGen, while Walder Wyss advised the funds managed by Pharmakon Advisors. ImmunoGen, Inc. (Nasdaq: IMGN) announced it has entered into a term loan...
You must be a Standard 1 Year member to access this content.
Greenberg Traurig represented Huadong Medicine on the deal, while Ropes & Gray advised Kiniksa Pharmaceuticals. Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., a wholly owned subsidiary of...
You must be a Standard 1 Year member to access this content.
Cravath and Lenz & Staehelin represented Taro in connection with the transaction. Ropes & Gray advised Galderma. Taro Pharmaceutical Industries Ltd. (“Taro”), a multinational, science-based pharmaceutical...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Blueprint Medicines in the deal. Blueprint Medicines annunced an exclusive collaboration and licensing agreement with Zai Lab Limited for the development and...
You must be a Standard 1 Year member to access this content.
Zhong Lun and Ropes & Gray advised LianBio on the deal. LianBio executed an initial public offering and listing of American depositary shares on the Nasdaq...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Takeda Pharmaceutical Company Limited in the deal. Takeda Pharmaceutical Company Limited announced an exclusive collaboration and license agreement with JCR Pharmaceuticals Co.,...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Sunovion Pharmaceuticals on the deal while Cooley represented Otsuka Pharmaceutical. Sunovion Pharmaceuticals Inc., a subsidiary of Japan’s Sumitomo Dainippon Pharma, signed a...
You must be a Standard 1 Year member to access this content.
Ropes & Gray represented Adaptimmune in the deal. Adaptimmune signed its strategic collaboration with Roche Group’s Genentech Inc. to research, develop and commercialize cancer-target allogeneic T-cell...
You must be a Standard 1 Year member to access this content.
Ropes & Gray advised Shape Therapeutics in the deal. Shape Therapeutics entered into a strategic research collaboration and license agreement with Roche worth up to $3...
You must be a Standard 1 Year member to access this content.
